JP2014501224A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014501224A5 JP2014501224A5 JP2013529237A JP2013529237A JP2014501224A5 JP 2014501224 A5 JP2014501224 A5 JP 2014501224A5 JP 2013529237 A JP2013529237 A JP 2013529237A JP 2013529237 A JP2013529237 A JP 2013529237A JP 2014501224 A5 JP2014501224 A5 JP 2014501224A5
- Authority
- JP
- Japan
- Prior art keywords
- granules
- intermediate layer
- coated
- active ingredient
- pharmaceutically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011248 coating agent Substances 0.000 description 36
- 238000000576 coating method Methods 0.000 description 36
- 239000008187 granular material Substances 0.000 description 29
- 239000007921 spray Substances 0.000 description 20
- 239000004480 active ingredient Substances 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000010419 fine particle Substances 0.000 description 13
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 239000000454 talc Substances 0.000 description 10
- 229910052623 talc Inorganic materials 0.000 description 10
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 10
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 8
- 229960003943 hypromellose Drugs 0.000 description 8
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 239000002245 particle Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 238000005096 rolling process Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000007931 coated granule Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 1
- 229920003114 HPC-L Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061427384P | 2010-12-27 | 2010-12-27 | |
| US61/427,384 | 2010-12-27 | ||
| PCT/JP2011/080568 WO2012091153A2 (en) | 2010-12-27 | 2011-12-26 | Orally disintegrating tablet |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014501224A JP2014501224A (ja) | 2014-01-20 |
| JP2014501224A5 true JP2014501224A5 (enExample) | 2015-01-22 |
Family
ID=45509604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013529237A Pending JP2014501224A (ja) | 2010-12-27 | 2011-12-26 | 口腔内崩壊錠 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20130273157A1 (enExample) |
| EP (1) | EP2658530A2 (enExample) |
| JP (1) | JP2014501224A (enExample) |
| KR (1) | KR20140007364A (enExample) |
| CN (1) | CN103402500A (enExample) |
| AR (1) | AR084610A1 (enExample) |
| AU (1) | AU2011350396A1 (enExample) |
| BR (1) | BR112013014875A2 (enExample) |
| CA (1) | CA2823166C (enExample) |
| CL (1) | CL2013001793A1 (enExample) |
| CO (1) | CO6731132A2 (enExample) |
| CR (1) | CR20130327A (enExample) |
| EA (1) | EA028217B1 (enExample) |
| EC (1) | ECSP13012718A (enExample) |
| MA (1) | MA34768B1 (enExample) |
| MX (1) | MX2013007588A (enExample) |
| PE (1) | PE20141115A1 (enExample) |
| PH (1) | PH12013501391A1 (enExample) |
| SG (2) | SG10201602311XA (enExample) |
| TN (1) | TN2013000220A1 (enExample) |
| TW (1) | TW201304823A (enExample) |
| UY (1) | UY33841A (enExample) |
| WO (1) | WO2012091153A2 (enExample) |
| ZA (1) | ZA201304617B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2254556A2 (en) | 2008-03-11 | 2010-12-01 | Takeda Pharmaceutical Company Limited | Orally-disintegrating solid preparation |
| US9012450B2 (en) | 2011-12-28 | 2015-04-21 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| PL2797416T3 (pl) | 2011-12-28 | 2017-12-29 | Global Blood Therapeutics, Inc. | Podstawione związki benzaldehydowe i sposoby ich zastosowania do zwiększania natlenienia tkanek |
| GB201303781D0 (en) | 2013-03-04 | 2013-04-17 | Gauthier Pierre Pascal | Oral timer device and method of using same |
| EP2968299B1 (en) | 2013-03-15 | 2021-01-20 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| JP6426694B2 (ja) | 2013-03-15 | 2018-11-21 | グローバル ブラッド セラピューティクス インコーポレイテッド | ヘモグロビンの修飾のための化合物及びその使用 |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| BR112015021982B1 (pt) | 2013-03-15 | 2022-12-13 | Global Blood Therapeutics, Inc | Compostos e seus usos para a modulação de hemoglobina |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| AP2016009261A0 (en) | 2014-02-07 | 2016-06-30 | Global Blood Therapeutics Inc | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| EP3218349A2 (en) | 2014-11-14 | 2017-09-20 | Gemphire Therapeutics Inc. | Processes and intermediates for preparing , -dicarboxylic acid-terminated dialkane ethers |
| US20170042806A1 (en) | 2015-04-29 | 2017-02-16 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| PL3383392T3 (pl) | 2015-12-04 | 2025-11-17 | Global Blood Therapeutics, Inc. | Schematy dawkowania dla 2-hydroksy-6-((2-(1-izopropylo-1H-pirazol-5-ilo)pirydyn3-ylo)metoksy)benzaldehydu |
| TWI663160B (zh) | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| TW202332423A (zh) * | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| EP3612171A4 (en) | 2017-04-18 | 2020-10-21 | Gemphire Therapeutics Inc. | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND PROCEDURES FOR THE USE OF THE SAME |
| WO2018209257A1 (en) * | 2017-05-11 | 2018-11-15 | Gemphire Therapeutics Inc. | Gemcabene compositions and methods of use thereof |
| MY200542A (en) * | 2017-07-10 | 2024-01-02 | Takeda Pharmaceuticals Co | Preparation comprising vonoprazan |
| CN108576205B (zh) * | 2018-03-22 | 2022-01-04 | 湖北省农业科学院农产品加工与核农技术研究所 | 一种草莓联合干燥的处理方法 |
| EP3860975B1 (en) | 2018-10-01 | 2023-10-18 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| JPH072761B2 (ja) | 1985-03-20 | 1995-01-18 | 不二パウダル株式会社 | 微結晶セルロ−ス球形顆粒及びその製造法 |
| JPS62277322A (ja) | 1986-02-13 | 1987-12-02 | Takeda Chem Ind Ltd | 安定化された腸溶性抗潰瘍固形組成物 |
| FR2679451B1 (fr) | 1991-07-22 | 1994-09-09 | Prographarm Laboratoires | Comprime multiparticulaire a delitement rapide. |
| JP3069458B2 (ja) | 1992-01-29 | 2000-07-24 | 武田薬品工業株式会社 | 口腔内崩壊型錠剤およびその製造法 |
| JP2919771B2 (ja) | 1995-04-17 | 1999-07-19 | 佐藤製薬株式会社 | 速溶解性錠剤の製造方法及び該製造方法により製造した速溶解性錠剤 |
| JPH0948726A (ja) | 1995-08-07 | 1997-02-18 | Tanabe Seiyaku Co Ltd | 口腔内速崩壊性製剤およびその製法 |
| JP3828648B2 (ja) | 1996-11-14 | 2006-10-04 | 武田薬品工業株式会社 | ２−（２−ピリジルメチルスルフィニル）ベンズイミダゾール系化合物の結晶およびその製造法 |
| TW385306B (en) | 1996-11-14 | 2000-03-21 | Takeda Chemical Industries Ltd | Method for producing crystals of benzimidazole derivatives |
| PT1121103E (pt) | 1998-05-18 | 2007-02-28 | Takeda Pharmaceutical | Comprimidos de desintegração oral compreendendo um benzimidazole |
| ES2237121T3 (es) | 1998-07-28 | 2005-07-16 | Takeda Pharmaceutical Company Limited | Preparacion solida disgregable rapidamente. |
| TWI275587B (en) | 1999-06-17 | 2007-03-11 | Takeda Chemical Industries Ltd | A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
| WO2001083473A1 (en) | 2000-04-28 | 2001-11-08 | Takeda Chemical Industries, Ltd. | Process for producing optically active sulfoxide derivative |
| CA2409044C (en) | 2000-05-15 | 2013-02-19 | Takeda Chemical Industries, Ltd. | Improved recrystallization processes for obtaining anhydrous optically active lansoprazole |
| KR20100002278A (ko) | 2000-12-01 | 2010-01-06 | 다케다 야쿠힌 고교 가부시키가이샤 | (ｒ)- 또는 (ｓ)-란소프라졸의 결정 |
| JP4493970B2 (ja) | 2002-10-16 | 2010-06-30 | 武田薬品工業株式会社 | 持続性製剤 |
| US20050214371A1 (en) * | 2004-03-03 | 2005-09-29 | Simona Di Capua | Stable pharmaceutical composition comprising an acid labile drug |
| JP2009519334A (ja) * | 2005-12-20 | 2009-05-14 | テバ ファーマシューティカル インダストリーズ リミティド | ランソプラゾール経口崩壊錠剤 |
| US20070141151A1 (en) * | 2005-12-20 | 2007-06-21 | Silver David I | Lansoprazole orally disintegrating tablets |
| EP1837016A3 (en) * | 2006-03-08 | 2008-01-02 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical multiple-unit composition |
| US9486446B2 (en) * | 2006-12-28 | 2016-11-08 | Takeda Pharmaceutical Company Limited | Orally disintegrating solid preparation |
| EP2254556A2 (en) * | 2008-03-11 | 2010-12-01 | Takeda Pharmaceutical Company Limited | Orally-disintegrating solid preparation |
| WO2010008569A1 (en) * | 2008-07-17 | 2010-01-21 | Barr Laboratories, Inc. | Orally disintegrating solid pharmaceutical dosage forms comprising delayed-release lansoprazole and methods of making and using the same |
-
2011
- 2011-12-26 TW TW100148775A patent/TW201304823A/zh unknown
- 2011-12-26 CA CA2823166A patent/CA2823166C/en active Active
- 2011-12-26 KR KR1020137019795A patent/KR20140007364A/ko not_active Withdrawn
- 2011-12-26 UY UY0001033841A patent/UY33841A/es not_active Application Discontinuation
- 2011-12-26 JP JP2013529237A patent/JP2014501224A/ja active Pending
- 2011-12-26 SG SG10201602311XA patent/SG10201602311XA/en unknown
- 2011-12-26 CN CN2011800685821A patent/CN103402500A/zh active Pending
- 2011-12-26 MX MX2013007588A patent/MX2013007588A/es not_active Application Discontinuation
- 2011-12-26 SG SG2013040944A patent/SG190905A1/en unknown
- 2011-12-26 EP EP11811174.9A patent/EP2658530A2/en not_active Withdrawn
- 2011-12-26 AU AU2011350396A patent/AU2011350396A1/en not_active Abandoned
- 2011-12-26 US US13/997,862 patent/US20130273157A1/en not_active Abandoned
- 2011-12-26 PH PH1/2013/501391A patent/PH12013501391A1/en unknown
- 2011-12-26 EA EA201390981A patent/EA028217B1/ru not_active IP Right Cessation
- 2011-12-26 WO PCT/JP2011/080568 patent/WO2012091153A2/en not_active Ceased
- 2011-12-26 BR BR112013014875A patent/BR112013014875A2/pt active Search and Examination
- 2011-12-26 PE PE2013001471A patent/PE20141115A1/es not_active Application Discontinuation
- 2011-12-27 AR ARP110104955A patent/AR084610A1/es unknown
-
2013
- 2013-05-24 TN TNP2013000220A patent/TN2013000220A1/fr unknown
- 2013-06-19 CL CL2013001793A patent/CL2013001793A1/es unknown
- 2013-06-21 ZA ZA2013/04617A patent/ZA201304617B/en unknown
- 2013-06-25 EC ECSP13012718 patent/ECSP13012718A/es unknown
- 2013-06-27 CR CR20130327A patent/CR20130327A/es not_active Application Discontinuation
- 2013-06-28 MA MA36063A patent/MA34768B1/fr unknown
- 2013-07-25 CO CO13176405A patent/CO6731132A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2823000T3 (es) | Formulaciones muco-adhesivas de liberación controlada de levodopa y/o ésteres de levodopa y usos de las mismas | |
| ES2428064T3 (es) | Sistemas de liberación pulsátil controlada | |
| CN101977593B (zh) | 包含弱碱性药物以及有机酸的给药系统 | |
| JP6368242B2 (ja) | ４０−ｏ−（２−ヒドロキシ）エチル−ラパマイシンを含む医薬組成物 | |
| JP2011513204A5 (enExample) | ||
| JP6356215B2 (ja) | エベロリムスを含む医薬組成物 | |
| ES2623176T3 (es) | Composición farmacéutica de memantina | |
| CN103181914B (zh) | 盐酸美金刚缓释胶囊及其制备方法 | |
| WO2018072709A1 (zh) | 医药微丸的干粉包衣组合物 | |
| JP2014515356A5 (enExample) | ||
| WO2014030204A1 (ja) | 薬物含有中空粒子 | |
| WO2007138022A2 (en) | Lipoic acid pellets | |
| CN103889455A (zh) | 稳定化乙哌立松医药组成物及含有上述组成物的缓释制剂 | |
| CN101601663A (zh) | 左乙拉西坦的多单元缓释制剂及其制备方法 | |
| CN1186014C (zh) | 程序化和随时间释放的多颗粒药物剂型及其制备方法 | |
| AU2017297117A1 (en) | Oral pharmaceutical preparation having improved content uniformity, containing tamsulosin hydrochloride-containing extended release pellet | |
| US20090192228A1 (en) | Controlled-Release Tolterodine Compositions and Methods | |
| JP5973170B2 (ja) | 固体分子分散物 | |
| TWI522113B (zh) | 用以製備活性組份顆粒之新穎方法，及製得之顆粒 | |
| CN101495097A (zh) | 球形素颗粒及其制造方法 | |
| JP2012025683A (ja) | 苦味を有する生理活性物質含有粒子の製造方法 | |
| WO2013186311A1 (en) | Extended release formulations | |
| US20080069870A1 (en) | Controlled Release Compositions Comprising a Cephalosporin for the Treatment of a Bacterial Infection | |
| Sun et al. | Preparation of microparticles for acid-labile lansoprazole by solvent evaporation method combined with a spray drying process | |
| US9498441B2 (en) | Nitazoxadine composition and process to prepare same |